Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia May 11, 2017
Safety and Efficacy Data from NODE-1 Trial Highlighted in Late Breaking Oral Session at Heart Rhythm Society’s 38th Annual Scientific Sessions
Successful NODE-1 Data Supports Advancement into Phase 3 Trials in PSVT Patients
Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer March 7, 2017
Montreal, QC, CA, March 7, 2017 -- Milestone Pharmaceuticals USA, Inc., a clinical stage cardiovascular company, today announced the appointment of Joseph G. Oliveto as President and Chief Executive Officer, effective immediately.
Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia January 25, 2016
MONTREAL, QC, January 25th, 2016 – Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company, announced today that the United States Adopted Name (USAN) Council recently adopted “etripamil” as the unique non-proprietary or generic name for MSP-2017.
Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017 June 15, 2015
Montreal, QC, June 15, 2015 – Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company in Phase 2, today announced the close of a US$17 million Series B financing. The round was led by Domain Associates and included participation from all of Milestone’s existing investors including Fonds de solidarité FTQ (FSTQ), Pappas Ventures, BDC Capital, GO Capital, and iNovia Capital. The funding will be used to complete Phase 2 clinical development of MSP-2017. In connection with this financing, Domain’s Debra Liebert will join Milestone’s board of directors.
Montreal, QC, January 12, 2015 – Milestone Pharmaceuticals, Inc. announced today that it received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 study of MSP-2017 for the treatment of acute episodes of Paroxysmal Supraventricular Tachycardia (PSVT). The trial is expected to begin patient enrollment in early 2015.
Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients November 24, 2014
Montreal, QC, November 24, 2014 – Milestone Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial conducted in Melbourne, Australia of MSP-2017, a novel calcium channel antagonist for the potential treatment of paroxysmal supraventricular tachycardia (PSVT). The results demonstrated that an intra-nasal formulation of MSP-2017 was well tolerated at single doses up to and including 140 mg with an excellent safety profile, desirable PK properties including rapid onset, and validating proof of concept by PR interval prolongation as measured by ECG. Milestone expects to initiate a Phase 2 clinical trial of MSP-2017 in patients with PSVT during the first half of 2015
Milestone Pharmaceuticals Appoints Chief Medical Officer July 21, 2014
MONTREAL, QC, July 21, 2014 — Milestone Pharmaceuticals Inc., a cardiovascular drug development company, today announced the appointment of Francis Plat, MD, FAHA, as Chief Medical Officer of the Company. Dr. Plat is a board-certified cardiologist with extensive experience in cardiovascular drug development. Most recently, Dr. Plat was Vice President and Therapeutic Area Head, Atherosclerosis and Cardiovascular at Merck Research Laboratories.
MONTREAL, QC, October 28, 2013 – Milestone Pharmaceuticals Inc., a cardiovascular drug development company, today announced that it has initiated a Phase 1 clinical trial with MSP-2017. MSP-2017 is a novel short-acting calcium channel antagonist that has demonstrated modulation of conductivity at the AV node of the heart in preclinical models. Milestone is initially developing MSP-2017 as a nasal spray that could be self-administered at home by patients for an initial potential treatment of paroxysmal supraventricular tachycardia (PSVT). The Phase 1 single ascending dose study will evaluate the safety, tolerability and pharmacokinetics of MSP-2017 in healthy volunteers using a crossover design to assess two intranasal formulations of MSP-2017.
MONTREAL, QC, March 5, 2012 – Milestone Pharmaceuticals Inc., a cardiovascular drug development company, today announced the appointment of Paul F. Truex to its Board of Directors. Mr. Truex is Chief Executive Officer, Founder and a Director of Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing drugs to treat serious illnesses, including cardiovascular and autoimmune diseases.
MONTREAL, QC, June 13, 2011 – Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing. The round is led by Pappas Ventures, the Business Development Bank of Canada (BDC), and GO Capital. Other participating investors are Fonds de solidarité FTQ (FSTQ), and the company's previous investors, iNovia Healthcare Ventures, who played a key role during the Company's founding and was the lead investor in the earlier rounds, and Fonds Bio-Innovation.
MONTREAL, QC, August 7, 2007 — Fonds Bio-Innovation and MSBi Capital, two venture capital funds that specialize in the financing of biotechnology start-ups, have participated in a C$2.75M (US$2.6M) financing round that Milestone Pharmaceuticals Inc. ("Milestone") has just closed.